CompaniesHealthcareHealthcarePharmaceuticals & Biotechnology

TRANSCHEM LTD.

Healthcare › Pharmaceuticals & Biotechnology
404.00
at close · 22 Sept 2026
4.00 (+1.00%)

Latest filings

  1. Transchem 49th AGM voting results: All 3 resolutions passed · Board & Shareholder Meetings
  2. Transchem 49th AGM: pivot to financial services, Greshma acquisition completed · Board & Shareholder Meetings
  3. Transchem acquires 100% of Greshma Shares and Stocks for about INR 25.91 crore · Strategic Transactions
  4. Transchem acquires 100% of Greshma Shares and Stocks for Rs 25.91 cr · Strategic Transactions
  5. Newspaper advertisement of Q1 FY27 unaudited financial results · Compliance
  6. Monitoring Agency Report on Transchem Preferential Warrant Issue Q1 FY27 · Fund Raising
  7. Transchem board approves amended Insider Trading Code · Compliance
  8. Transchem Q1 FY27 net profit surges to Rs 342 lakh · Results
  9. Board approves Q1 FY27 results, net profit up 3.4x at Rs 342 lakh · Board & Shareholder Meetings
  10. Board meeting on Aug 10 to consider Q1 FY27 unaudited results · Results
  11. Newspaper ad for 49th AGM notice and remote e-voting info · Compliance
  12. Transchem 49th AGM notice and FY26 annual report dispatch · Board & Shareholder Meetings
  13. 49th AGM on Sept 5, 2026; book closure Aug 30 to Sept 5; FY26 annual report filed · Board & Shareholder Meetings
  14. Transchem 49th AGM on Sep 5, 2026; book closure Aug 30 to Sep 5 · Board & Shareholder Meetings
  15. Routine RTA compliance certificate under SEBI Reg 74(5) for Q1 FY27 · Compliance
  16. Trading Window Closure Ahead of Q1 FY26 Results · Compliance
  17. The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bakkt Opco Holdings, LLC · Ownership Changes
  18. The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pishu V Chainani · Ownership Changes
  19. Please refer the attached intimation. · Fund Raising
  20. Please refer the attached intimation. · Fund Raising
  21. Please refer the attached intimation. · Compliance
  22. Please refer the attached intimation. · Fund Raising
  23. Please refer the attached intimation. · Compliance
  24. Please refer the attached intimation. · Fund Raising
  25. <b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> .... · Compliance
  26. Please refer the attached intimation · Compliance
  27. Re-appointment of M/s. L. T. Jadav & Co., Chartered Accountants as the Internal Auditors of the Company for the F.Y. 2026-2027 · General
  28. Please refer the attached intimation · Results
  29. Please refer the attached intimation · Results
  30. Transchem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2026 ,inter alia, to consider and approve the Audited Financial Results of .... · Results
  31. <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> .... · Compliance
  32. Please refer the attached intimation. · Compliance
  33. Please refer the attached intimation. · Compliance
  34. Please refer the attached intimation. · Compliance
  35. Please refer the attached intimation. · Results
  36. Please refer the attached intimation. · Results
  37. Transchem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 ,inter alia, to consider and approve Un-Audited Financial Results of .... · Results
  38. Please refer the attached intimation. · Compliance
  39. Please refer the attached intimation. · Compliance
  40. Please refer the attached intimation. · Corporate Actions
  41. Please refer the attached intimation. · Board & Shareholder Meetings
  42. Please refer the attached intimation. · Board & Shareholder Meetings
  43. Please refer the attached intimation. · Compliance
  44. Please refer the attached Intimation. · Board & Shareholder Meetings
  45. Please refer the attached intimation. · Compliance
  46. Please refer the attached intimation. · Board & Shareholder Meetings
  47. Please refer the attached Intimation. · Board & Shareholder Meetings
  48. Please refer the attached Intimation. · Board & Shareholder Meetings
  49. Please refer the attached Intimation. · Board & Shareholder Meetings
  50. Please refer the attached intimation. · Fund Raising
All filings ↓
Ask Nexa about TRANSCHEM LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Classified under pharmaceuticals, the company reported total income of Rs 926.08 lakhs in FY26, but operating revenue in Q3 FY26 was just Rs 20.60 lakhs — the bulk of income came from 'other income' sources. It holds cash reserves of Rs 4,242.91 lakh and posted net profit of Rs 429.51 lakhs, though operating cash flow turned negative at minus Rs 156.59 lakh for the year. The company has allotted 6.15 crore warrants at Rs 75 each, of which Rs 110 crore of proceeds is earmarked for strategic acquisitions in the broking and allied financial services sector, with target entities intended to become subsidiaries. Another Rs 115 crore is allocated for general corporate purposes to be utilised within 6-18 months. The largest allottee is Bakkt Opco Holdings, LLC (a US entity owned by NYSE-listed Bakkt Inc.), which received 4.75 crore warrants representing 64.42% of fully diluted share capital upon conversion.

Operating scale
Total income FY26
Rs 926.08 lakhsFY26
Cash reserves
Rs 4,242.91 lakhFY26
Warrants allotted
6.15 crore warrants at Rs 75 eachJun 2026
Bakkt Opco Holdings stake on conversion
64.42% of fully diluted capitalJun 2026
Net profit FY26
Rs 429.51 lakhsFY26
Kind of business
Pharmaceutical classification with minimal operating revenue; cash-rich and raising capital to pivot toward broking and financial services
Market Cap
₹495 Cr
P / E (TTM)
115.1×
EV / EBITDA
80.5×
Div Yield
Growth
·
Revenue 5y CAGR
PAT -29.2% · EBITDA -25.8%
Quality
6.7%·
ROCE (5y median)
ROE 5.1% · margin —
Leverage
0.00·
Debt / Equity · low
Net debt ₹-42 Cr
Cash conversion
1.02×
Operating cash ÷ profit · 5 yrs
₹18 Cr on ₹18 Cr
Moves on a normal day
2.00%·
Median daily move
Last 268 sessions · filing days run larger
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#163/170
P/B#127/164
ROCE#118/183
ROE#120/171
Debt / Equity#6/171
Revenue growth#157/161
Profit growth#25/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Debt at 0.00× equity
lower than 77% of its 171 Pharmaceuticals peers
Over 5 years it reported ₹18 Cr of profit and ₹18 Cr of operating cash — 1.02×
Profit is converting into cash
Concerns
Profit shrinking over 5 years (-29% a year)
Erratic profits — up in only 2 of the last 5 years

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from TRANSCHEM LTD.'s filed financials and exchange disclosures

What does TRANSCHEM LTD. do?

TRANSCHEM LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.

Is TRANSCHEM LTD. profitable?

Yes. Over the trailing twelve months TRANSCHEM LTD. reported a net profit of ₹4 Cr on revenue of ₹0 Cr.

Does TRANSCHEM LTD. pay a dividend?

Not in the latest reported year — TRANSCHEM LTD.'s dividend payout for FY26 was nil.

Is TRANSCHEM LTD. debt-free?

Effectively yes. It holds ₹42 Cr more cash than debt. Debt stands at 0.00× equity.

Is TRANSCHEM LTD. expensive compared with its peers?

On trailing P/E, TRANSCHEM LTD. ranks 163 of 170 in Pharmaceuticals — cheaper than 4% of them, against an industry median of 29.6×. This is a position, not a valuation judgement.

How much does the TRANSCHEM LTD. share price move in a day?

On a typical session TRANSCHEM LTD. moves 2.00% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.

Where can I track TRANSCHEM LTD.'s announcements?

Every NSE and BSE filing by TRANSCHEM LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.